Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast

The small-cell lung cancer (SCLC) treatment landscape is dominated by chemotherapy and chemoradiotherapy. In the last 30 years, only two immunotherapies have been approved in this indication: Genentech’s Tecentriq in 2019 and AstraZeneca’s Imfinzi in 2020 for treatment of extensive-stage disease across the G7 markets. Despite approval of these drugs, a substantial unmet need remains for better therapeutic options, especially in the later lines of therapy. However, the modest late-phase pipeline for SCLC is set to boost the market—namely, with Amgen’s bispecific T-cell engager (BiTE) tarlatamab and Daiichi’s antibody-drug conjugate (ADC) ifinatamab deruxtecan. Nevertheless, considerable commercial potential remains for targeted agents that treat the underserved relapsed/refractory SCLC population.

Questions Answered

  • What are interviewed experts’ insights on the current treatment options for SCLC?
  • How large are the drug-treatable SCLC populations, and how will drug-treatment rates change over time?
  • How will key emerging therapies shape the SCLC market over the 10-year forecast period?
  • What key factors are driving or constraining market growth?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

launch Related Market Assessment Reports